*Joslin Diabetes Center, Beetham Eye Institute, Harvard Department of Ophthalmology, Boston, Massachusetts;

†Jaeb Center for Health Research, Tampa, Florida;

‡Ophthalmic Research Consultants, LLC. Waxhaw, North Carolina;

§Midwest Eye Institute, Indianapolis, Indiana;

¶ Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana;

** Wolfe Eye Clinic, Des Moines, Iowa;

†† Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; and

‡‡ Feinberg School of Medicine, Northwestern University Medical School, Chicago, Illinois.

Reprint requests: Wesley T. Beaulieu, PhD, Jaeb Center for Health Research, Tampa, FL; e-mail: [email protected]

Research reported in this publication was supported by the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number UG1EY014231. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Regeneron provided funding and aflibercept for Protocols T and V; Genentech provided funding and ranibizumab for Protocols I and T (bevacizumab compounded by a central pharmacy was used off-label in protocol T); Allergan provided funding and study drug for Protocol I. The DRCR Retina Network had complete control over the design of the protocol, ownership of the data, all editorial content of presentations and publications related to the protocol, and the decision to submit for publication.

None of the authors has any financial/conflicting interests to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.retinajournal.com).

The funding organization (National Institutes of Health) participated in oversight of the conduct of the study and review of the manuscript but not directly in the design or conduct of the study, nor in the collection, management, analysis, or interpretation of the data, or in the decision to submit for publication or the preparation of the manuscript.